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P R E V I E W SXenobiotic receptor meets NF-kB,
a collision in the small bowel
It has long been appreciated that inflammation and infection reduce drug metabolism and that exposure to drug metabo-
lism-inducing xenobiotics can impair immune function. A new study reveals the mutual repression between the xenobiotic
nuclear receptor PXR/SXR and NF-kB signaling pathways, providing amolecular mechanism linking xenobiotic metabolism
and inflammation (Zhou et al., 2006).Gene and environment interactions are a
vital force that constantly shape living
organisms. In dealing with xenobiotics,
mammals have evolved a defensive net-
work governed by the so-called xenobi-
otic receptors/xeno-senors, such as
pregnane X receptor (PXR, also known
as steroid and xenobiotic receptor or
SXR) and constitutive androstane recep-
tor (CAR). When encountering infectious
agents, organisms have enlisted the in-
nate and adaptive immune defensive
systems, in which the nuclear factor
kappa B (NF-kB) plays an essential regu-
latory role. Armed with the chemical and
immunological defensive systems, mam-
mals by and large cope well with the
challenge of noxious substances or in-
fectious agents that have been part of
their life. However, these two defensive
systems do not always run in sync; in
some cases one prevails at the cost of
the other. It has been known in the clinic
that inflammation and infection reduce
hepatointestinal drug metabolism ca-
pacity (Aitken et al., 2006). Meanwhile,
drug metabolism-inducing xenobiotics/
drugs, such as the antibiotic rifampicin,
are known to repress the immune system
(Paunescu, 1970). In the July issue of the
Journal of Clinical Investigation, Zhou
et al. demonstrated mutual suppression
between PXR/SXR and NF-kB, providing
a potential molecular mechanism that
links xenobiotic metabolism and inflam-
mation (Zhou et al., 2006).
PXR/SXR was isolated as an orphan
nuclear receptor that regulates the me-
tabolism and disposition of various xeno-
biotics and endobiotics. The xeno-sen-
sor function of PXR is achieved through
its coordinated transcriptional regulation
of Phase I and Phase II drugmetabolizing
enzymes as well as the ‘‘Phase III’’ drug
transporters (Xie et al., 2004). The flexibil-
ity in its ligand binding pocket enables
PXR/SXR to function as a xenobiotic re-
ceptor through interacting with a wide
range of structurally diverse compounds.CELL METABOLISM : SEPTEMBER 2006Xeno- and endobiotics that activate
PXR/SXR include various prescription
drugs, herbal medicines, environmental
toxicants, and bile acids. Zhou and col-
leagues demonstrated that drugs that
typically activate human PXR/SXR, such
as rifampicin, suppressed the expression
of typical NF-kB target genes, such as
COX-2, TNFa, ICAM-1, and several inter-
leukins. In contrast, hepatocytes derived
from the PXR null mice showed elevated
NF-kB target gene expressions com-
pared to cells from the wild-type animals,
suggesting that PXR plays a role in sup-
pressing the NF-kB-regulated gene ex-
pression. Moreover, the PXR null mice
exhibited signs of heightened inflam-
mation in their small bowels (Zhou et al.,
2006).
NF-kB belongs to a family of evolution-
arily conserved eukaryotic transcription
factors that are pivotal in regulating in-
nate and adaptive immune responses
(Ghosh et al., 1998). In mammals, there
are five known NF-kB proteins, all shar-
ing a common 300 amino acid Rel
homology domain. These include NF-kB1
(p50 and its precursor p105), NF-kB2 (p52
and its precursor p100), c-Rel, RelA (p65),
and RelB. A typical NF-kB activation
involves the heterodimerization of p65
and p50 and subsequent binding of p65/
p50 heterodimers to NF-kB sites found
in the target gene promoters. NF-kB
proteins are normally sequestered in the
cytoplasm by inhibitor of NF-kB (IkB). The
NF-kB activation involves phosphoryla-
tion, ubiquitination and proteosome-
dependent degradation of IkB and sub-
sequent release of NF-kB for its nuclear
translocation and transcriptional activity.
NF-kB proteins are well known for their
swift activation in response to endotoxin
or proinflammatory cytokines. Activation
of NF-kB, however, is not without a cost;
the collateral damages include excessive
inflammatory reactions that may be in-
volved in septic shock, acute respiratory
distress syndrome, unwanted antiapop-totic activity that may allow neoplasm
to slip through, and decreases in xenobi-
otic/drug metabolism (Aitken et al., 2006;
Karin, 2006). Indeed, in this work, Zhou
et al. (2006) showed that NF-kB activa-
tion inhibited PXR/SXR and its primary
target gene CYP3A, whereas inhibition
of NF-kB enhanced PXR/SXR-mediated
activation of drug metabolizing enzymes.
Interestingly, Zhou et al. reported that
the increased inflammation in the PXR
null mice appeared to be specific for the
small bowel (Zhou et al., 2006). The rea-
son for this tissue specificity could be
due to the loss of negative regulation of
PXR on NF-kB, as suggested by these
investigators. However, it is also possi-
ble that the inflammatory lesions were
caused by inadequate metabolism and
clearance of toxic xeno- and endobiotic
substances from this tissue (Langmann
et al., 2004). Intriguingly, a recent report
suggests that reduced expression and/
or functional polymorphisms of PXR/SXR
are associated with inflammatory bowel
diseases (IBD) (Dring et al., 2006). This
evidence collectively suggests that dys-
regulation of PXR/SXR expression or
activity may predispose the GI track to
inflammatory injuries.
Although the mutual suppression be-
tweenPXR/SXRandNF-kBwasconvinc-
ingly demonstrated by Zhou et al. (2006),
this study falls short in pinpointing the
molecular linchpin that connects PXR/
SXR and NF-kB signaling pathways.
This deficiency, however, has been com-
plemented by several studies published
recently by other groups. In an effort to
understand the suppression of CYP3A4
by proinflammatory agents, Gu and col-
leagues showed that NF-kB activation
disrupted the binding of PXR/RXR heter-
odimers to a PXR response element
(PXRE) found in the CYP3A4 gene pro-
moter, providing a plausible molecular
mechanism for the suppression of drug
metabolism by proinflammatory signals
(Gu et al., 2006). In the same study,177
P R E V I E W SFigure 1. Mutual repression between PXR/SXR and NF-kB signaling pathways
The PXR/SXR and NF-kB mutual suppression may link xenobiotic metabolism and inflammation in the hepa-
tointestinal axis. IBD, inflammatory bowel disease; ICAM, intercellular adhesion molecule; LPS, lipopolysac-
charide; NF-kB, nuclear factor kappa B; PXR, pregnane X receptor; PXRE, PXR response element; SXR,
steroid and xenobiotic receptor; TNF, tumor necrosis factor.NF-kB RelA/p65 was shown to interact
with the highly conservedRXRDNAbind-
ing domain. This mode of suppression
may have broad implications, as RXR is
the obligate partner for xenobiotic recep-
tors PXR and CAR as well as nonxenobi-
otic receptors, such as vitamin D recep-
tor, which have also been implicated in
xenobiotic metabolism. As an example
of nuclear receptor-mediated suppres-
sion of NF-kB, recent work by Pascual
et al. showed that ligand-dependent and
residue-specific SUMOylation of PPARg
targeted this receptor to the promoter of
iNOS, a NF-kB target gene. This PPARg
targeting prevented the removal of core-
pressor complex from the iNOS pro-
moter, thus suppressing its positive regu-
lation by NF-kB (Pascual et al., 2005). It
remains to be seen whether a similar178mechanism is applicable in the suppres-
sion of NF-kB by PXR/SXR.
Regardless of the molecular details of
the interaction, themutual repression be-
tween PXR/SXR and NF-kB manifests
nature’s ‘‘checks andbalances’’ between
two pathways that are at the heart of
xenobiotic homeostasis and biodefense
of an organism (Figure 1). Since PXR can
also sense numerous endobiotics, it is
interesting to know whether or not there
is interplay between the endobiotic ho-
meostasis and inflammatory responses.
Whether the xenobiotic receptor-NF-kB
cross-talk is conserved for CAR or other
xenobiotic metabolism-implicating nu-
clear receptors is unknown. If the human
relevance of the findings in Zhou et al.
(2006) can be substantiated, one can
envision that certain PXR ligands maybe used to limit the intensity and duration
of NF-kB activation in a tissue-specific
manner, thus exerting anti-inflammatory
action. Reciprocally, the suppression of
the xenobiotic detoxification by inflam-
mation in IBD can be reversed through
inhibition of NF-kB activity, allowing PXR
to retain its transcriptional activity.
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